Nathan Rice

Stock Analyst at Piper Sandler

(3.08)
# 1,185
Out of 5,163 analysts
61
Total ratings
52.63%
Success rate
10.62%
Average return

Stocks Rated by Nathan Rice

Bank First
Jan 26, 2026
Maintains: Neutral
Price Target: $142$150
Current: $135.44
Upside: +10.75%
First Mid Bancshares
Nov 3, 2025
Maintains: Overweight
Price Target: $49$48
Current: $39.40
Upside: +21.83%
Merchants Bancorp
Oct 30, 2025
Maintains: Overweight
Price Target: $41$42
Current: $41.66
Upside: +0.82%
Byline Bancorp
Oct 28, 2025
Maintains: Overweight
Price Target: $34$35
Current: $30.50
Upside: +14.75%
CVS Health
May 2, 2024
Maintains: Buy
Price Target: $85$74
Current: $76.13
Upside: -2.80%
Nicolet Bankshares
Jan 10, 2024
Assumes: Neutral
Price Target: $84
Current: $149.21
Upside: -43.70%
Align Technology
Dec 11, 2023
Downgrades: Sell
Price Target: $197
Current: $164.23
Upside: +19.95%
Elanco Animal Health
Apr 25, 2023
Maintains: Sell
Price Target: $11$9
Current: $22.94
Upside: -60.77%
IDEXX Laboratories
Jul 21, 2022
Upgrades: Buy
Price Target: $530$435
Current: $573.82
Upside: -24.19%
The Cigna Group
Dec 14, 2021
Initiates: Neutral
Price Target: $233
Current: $267.19
Upside: -12.80%
Initiates: Neutral
Price Target: $83
Current: $34.45
Upside: +140.93%
Initiates: Overweight
Price Target: $15
Current: $19.48
Upside: -23.00%